Current position of chondroitin sulfate and glucosamine sulfate in the therapy of osteoarthritis

Osteoarthritis is a chronic disease that causes the development of permanent disability of the patient and is a significant social and economic burden on the health care system of developed countries. It should be noted that the current variability of approaches to the treatment of osteoarthritis is due to a number of factors, including differences in etiology, severity of course, and clinical symptomatology of the disease, which must be analyzed and taken into account when choosing therapy. The modern approach to therapy of osteoarthritis includes the use of symptomatic slow-acting drugs (SYSADOA). Objective: to review the literature data on the role of SYSADOA in the therapeutic arsenal of patients with osteoarthritis. Materials and methods. Literature review and analysis was conducted by keyword using electronic resources of PubMed, MedLine databases in the period from 2010 to 2023. Results. The analysis of the studies conducted to date on the establishment, validity and feasibility of the group of symptomatic slow-acting drugs in the therapy of OA to control the progression of the disease showed the presence of very controversial and debatable provisions, which is associated with a diverse range of available glucosamine and chondroitin sulfate drugs. The greatest evidence base and efficacy are found in prescription preparations of crystalline glucosamine sulfate and chondroitin sulfate. Conclusion. The use of SYSADOA requires further study, including randomized placebo-controlled trials using modern joint imaging techniques.

1. March L., Cross M., Lo C., Arden N. K., Gates L., Leyland K. M., Hawker G., King L.,Leyland K. (Accepted/In press). Osteoarthritis: A Serious Disease: Submitted to the U.S. Food and Drug Administration. URL: https://www.oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa_serious_disease_121416_1.pdf

2. Bruyère O., Honvo G., Veronese N., Arden N.K., Branco J., Curtis E.M., Al-Daghri N.M., Herrero-Beaumont G. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-350. DOI: 10.1016/j.semarthrit.2019.04.008.

3. Borisenko O.V., Belenkiy D.A. Effect of combination therapy with original glucosamine sulfate on pain syndrome in patients with osteoarthritis: A prospective post-marketing study. Clinical Medicine (Russian Journal). 2013;91(5):65-71 (in Russ.)

4. Railhac J.J., Zaim M., Saurel A.S., Vial J., Fournie B. Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI. Clin Rheumatol. 2012;31(9):1347-1357. DOI: 10.1007/s10067-012-2022-4. Erratum in: Clin Rheumatol. 2014;33(10):1527.

5. Kanzaki N., Saito K., Maeda A., Kitagawa Y., Kiso Y., Watanabe K., Tomonaga A., Nagaoka I., et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled study. J Sci Food Agric. 2012;92(4):862-869. DOI: 10.1002/jsfa.4660.

6. Fransen M., Agaliotis M., Nairn L., Votrubec M., Bridgett L., Su S., Jan S., March L., et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5):851-858. DOI: 10.1136/annrheumdis-2013-203954.

7. Singh J.A., Noorbaloochi S., MacDonald R., Maxwell L.J. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015;1(1):CD005614. DOI: 10.1002/14651858.CD005614.pub2.

8. Lapshina S.A., Afanasieva M.A., Sukhorukova E.V., Akhtyamov I.F., Myasoutova L.I. Study of the efficacy, safety and tolerability of the combined use of glucosamine sulfate («Artrakam») and chondroitin sulfate («Artradol») in patients with osteoarthritis of the knee. The Bulletin of Contemporary Clinical Medicine. 2016;9(1): 45-51 (in Russ.). DOI: 10.20969/vksm.2016.9(1).45-51.

9. Eckstein F., Boudreau R., Wang Z., Hannon M.J., Duryea J., Wirth W., Cotofana S., Guermazi A., et al.Comparison of radiographic joint space width and magnetic resonance imaging for prediction of knee replacement: A longitudinal case-control study from the Osteoarthritis Initiative. Eur Radiol. 2016;26(6):1942-1951. DOI: 10.1007/s00330-015-3977-8.

10. Roth M., Wirth W., Emmanuel K., Culvenor A.G., Eckstein F. The contribution of 3D quantitative meniscal and cartilage measures to variation in normal radiographic joint space width-Data from the Osteoarthritis Initiative healthy reference cohort. Eur J Radiol. 2017;87:90-98. DOI: 10.1016/j.ejrad.2016.12.009.

11. Podlipská J., Guermazi A., Lehenkari P., Niinimäki J., Roemer F.W., Arokoski J.P., Kaukinen P., Liukkonen E., et al.Comparison of Diagnostic Performance of Semi-Quantitative Knee Ultrasound and Knee Radiography with MRI: Oulu Knee Osteoarthritis Study. Sci Rep. 2016;6:22365. DOI: 10.1038/srep22365. Erratum in: Sci Rep. 2016;6:33109.

12. Santilli V., Paoloni M., Mangone M., Alviti F., Bernetti A. Hyaluronic acid in the management of osteoarthritis: injection therapies innovations. Clin Cases Miner Bone Metab. 2016;13(2):131-134. DOI: 10.11138/ccmbm/2016.13.2.131.

13. Roman-Blas J.A., Castañeda S., Sánchez-Pernaute O., Largo R., Herrero-Beaumont G.; CS/GS Combined Therapy Study Group.Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol. 2017;69(1):77-85. DOI: 10.1002/art.39819. Erratum in: Arthritis Rheumatol. 2017 Oct;69(10 ):2080.

14. Reginster J.Y., Dudler J., Blicharski T., Pavelka K. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis. 2017;76(9):1537-1543. DOI: 10.1136/annrheumdis-2016-210860.

15. Luneva S.N., Sazonova N.V., Malceva L.V., Matveeva E.L. Effectiveness of Theraflex® evaluation in early stages of osteoarthritis treatment and its influence on articular cartilage structure and metabolism. Consilium Medicum. 2018;20(9):63-70 (in Russ.). DOI: 10.26442/2075-1753_2018.9.63-70.

16. Hochberg M.C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010;18 Suppl 1:S28-31. DOI: 10.1016/j.joca.2010.02.016.

17. Gafarov I.R., Musina F.S., Glazunov S. Yu. Medium-term results of the effectiveness of combination therapy of glucosamine and chondroitin sulfate in osteoarthrosis of the knee joints. Health and education Millennium. 2018;20(4):51-57 (in Russ.). DOI: 10.26787/nydha.2018.20(4).51-57.

18. Nelson A.E. Osteoarthritis year in review 2017: clinical. Osteoarthritis Cartilage. 2018;26(3):319-325. DOI: 10.1016/j.joca.2017.11.014. Eriksen P., Bartels E.M., Altman R.D., Bliddal H., Juhl C., Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014;66(12):1844-1855. DOI: 10.1002/acr.22376.

19. Rovati L.C., Girolami F., D'Amato M., Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016;45(4 Suppl):S34-41. DOI: 10.1016/j.semarthrit.2015.10.009.

20. Gregori D., Giacovelli G., Minto C., Barbetta B., Gualtieri F., Azzolina D., Vaghi P., Rovati L.C. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018;320(24):2564-2579. DOI: 10.1001/jama.2018.19319.

21. Honvo G., Bruyère O., Geerinck A., Veronese N., Reginster J.Y. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Adv Ther. 2019;36(5): 1085-1099. DOI: 10.1007/s12325-019-00921-w.

22. Pelletier J.P., Raynauld J.P., Beaulieu A.D., Bessette L., Morin F., de Brum-Fernandes A.J., Delorme P., Dorais M., et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016;18(1):256. DOI: 10.1186/s13075-016-1149-0.

23. Lila A.M., Alekseeva L.I., Telyshev K.A., Baranov A.A., Trofimov E.A. The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study. Modern Rheumatology Journal. 2020;14(3):71-78. (in Russ.). DOI:10.14412/1996-7012-2020-3-71-78.

24. Karateev A.E., Barysheva Yu.V., Belokon Y.V., Bolshakova T.Yu., Grabovetskaya Yu.Yu., Dolzhenkova E.A., Eliseeva L.N., Ershova O.B., et al. Evaluation of the efficacy and safety of a combination of chondroitin sulfate and glucosamine sulfate for knee and hip osteoarthritis in real clinical practice. Modern Rheumatology Journal. 2020;14(4):82-90 (in Russ.). DOI: 10.14412/1996-7012-2020-4-82-90.

25. Beaudart C., Lengelé L., Leclercq V., Geerinck A., Sanchez-Rodriguez D., Bruyère O., Reginster J.Y. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020;80(18):1947-1959. DOI: 10.1007/s40265-020-01423-8.

26. Gnylorybov A.M., Ter-Vartanian S.K., Golovach I.Y., Vyrva O.E., Burianov O.A., Yesirkepova G.S., Irismetov M.E., Rizamuhamedova M.Z., et al. Expert Opinion on the Extensive Use of Prescription Crystalline Glucosamine Sulfate in the Multimodal Treatment of Osteoarthritis in Ukraine, Kazakhstan, Uzbekistan, and Armenia. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120946743. DOI: 10.1177/1179544120946743.

27. Zhang Z., Huang C., Cao Y., Mu R., Zhang M.C., Xing D., Fan D., Ding Y., et al. 2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. Aging Clin Exp Res. 2021;33(8): 2141-2147. DOI: 10.1007/s40520-021-01906-y.

28. Honvo G., Reginster J.Y., Rabenda V., Geerinck A., Mkinsi O., Charles A., Rizzoli R., Cooper C., et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):65-99. DOI: 10.1007/s40266-019-00662-z.

29. Denisov L.N., Alekseeva L.I., Zotkin E.G., Dydykina I.S., Lila A.M., Rodionova S.S., Kochish A.Yu., Trofimov E.A., et al. Evidence-based therapy for knee osteoarthritis: expected short-, medium-, and long-term outcomes of prescription crystalline glucosamine sulfate administration. Modern Rheumatology Journal. 2022;16(4):80-87 (in Russ.). DOI: 10.14412/1996-7012-2022-4-80-87.

30. Wang Z., Wang R., Yao H., Yang J., Chen Y., Zhu Y., Lu C. Clinical Efficacy and Safety of Chondroitin Combined with Glucosamine in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis.Comput Math Methods Med. 2022;2022:5285244. DOI: 10.1155/2022/5285244.

31. Meng Z., Liu J., Zhou N. Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis. Arch Orthop Trauma Surg. 2023;143(1):409-421. DOI: 10.1007/s00402-021-04326-9.

32. Lila A.M., Chuchalin A.G., Torshin I.Yu., Gromova O.A. Important aspects of osteoarthritis therapy during the COVID-19 pandemic. Modern Rheumatology Journal. 2022;16(1):108-114 (in Russ.). DOI: 10.14412/1996-7012-2022-1-108-114.

33. Gromova O.A., Torshin I.Yu., Lila A.M., Naumov A.V., Malyavskaya S.I. Prospects for the use of micronutrients in the treatment of coronavirus infection in patients with comorbid pathology.Russian Medical Inquiry. 2020;4(8):504-510 (in Russ.). DOI: 10.32364/2587-6821-2020-4-8-504-510.

34. Gromova O.A., Torshin I.Yu., Lila A.M., Gromov A.N. Molecular mechanisms of action of glucosamine sulfate in the treatment of degenerative-dystrophic diseases of the joints and spine: results of proteomic analysis. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):38-44 (in Russ.). DOI: 10.14412/ 2074-2711-2018-2-38-44.

35. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., Towheed T., Welch V., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-474. DOI: 10.1002/acr.21596.

36. McAlindon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M., Hawker G.A., Henrotin Y., et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-388. DOI: 10.1016/j.joca.2014.01.003.

37. Miller L.E., Sloniewsky M.J., Gibbons T.E., Johnston J.G., Vosler K.D., Nasir S. Long-term clinical benefit and cost-effectiveness of an 8-week multimodal knee osteoarthritis management program incorporating intra-articular sodium hyaluronate (Hyalgan®) injections. J Pain Res. 2017;10:1045-1054. DOI: 10.2147/JPR.S132497.

38. Paoloni M., Bernetti A., Belelli A., Brignoli O., Buoso S., Caputi A.P., Catani F., Coclite D., et al. Appropriateness of clinical and organizational criteria for intra-articular injection therapies in osteoarthritis. A Delphi method consensus initiative among experts in Italy. Ann Ist Super Sanita. 2015;51(2):131-138. DOI: 10.4415/ANN_15_02_11.